Familial Amyloid Polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Familial Amyloid Polyneuropathy (FAP)

Familial amyloid polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid polyneuropathy is a progressive sensorimotor and autonomic neuropathy of adulthood onset. FAP is transmitted as an autosomal dominant trait and is caused by mutations in the TTR gene (18q12.1). The most common variant is the TTR Val30Met substitution for which several endemic foci have been identified most notably from Portugal, Japan and Sweden.

Epidemiology- According to literature review and Thelansis estimation, It occurs in approximately one in 5,000 to 10,000 individuals in the United States and accounts for about 0.5% of all cases of colorectal cancer. According to national registries, familial adenomatous polyposis occurs in 2.29-3.2 per 100,000 individuals.

Competitive landscape of Familial Amyloid Polyneuropathy (FAP) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Familial Amyloid Polyneuropathy (FAP) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Familial Amyloid Polyneuropathy (FAP) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Familial Amyloid Polyneuropathy (FAP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        Celebrex        Pfizer Inc.        Astellas       

Withdrawn from Market

2        ALFA        S.L.A. Pharma AG        N/A        III

3        CPP-1X/Sulindac        Mallinckrodt plc        Zeria; Cancer Prevention        III

4        Tremfya        Johnson & Johnson        MorphoSys; Otsuka        I

5        CPP-1X        Cancer Prevention Pharmaceuticals, Inc.        N/A        Preclinical